147 related articles for article (PubMed ID: 2496560)
1. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Gersuk GM; Carmel R; Pattengale PK
Blood; 1989 Nov; 74(7):2330-4. PubMed ID: 2804368
[TBL] [Abstract][Full Text] [Related]
3. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
[TBL] [Abstract][Full Text] [Related]
4. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
5. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
6. [Megakaryoblastic transformation in polycythemia vera--a case of megakaryoblastic leukemia associated with myelofibrosis and elevation of serum PDGF-like activity].
Oda K; Katoh O; Kawano M; Iwato K; Kimura A; Imamura N; Fujimura K; Kuramoto A; Yasui W; Kajihara H
Rinsho Ketsueki; 1986 Nov; 27(11):2118-23. PubMed ID: 3820629
[No Abstract] [Full Text] [Related]
7. Intracellular growth factors in polycythemia vera and other myeloproliferative disorders.
Eid J; Ebert RF; Gesell MS; Spivak JL
Proc Natl Acad Sci U S A; 1987 Jan; 84(2):532-6. PubMed ID: 3467372
[TBL] [Abstract][Full Text] [Related]
8. Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders.
Parise P; Huybrechts E; Grasselli S; Falcinelli F; Nenci GG; Gresele P; Vermylen J
Acta Haematol; 1991; 85(2):88-92. PubMed ID: 1902615
[TBL] [Abstract][Full Text] [Related]
9. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
10. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.
Villmow T; Kemkes-Matthes B; Matzdorff AC
Thromb Res; 2002 Nov; 108(2-3):139-45. PubMed ID: 12590950
[TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease.
Bernabei PA; Arcangeli A; Casini M; Grossi A; Padovani R; Rossi Ferrini P
Br J Haematol; 1986 Jun; 63(2):353-7. PubMed ID: 3755056
[TBL] [Abstract][Full Text] [Related]
12. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
13. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
14. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Wehmeier A; Fricke S; Scharf RE; Schneider W
Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
[TBL] [Abstract][Full Text] [Related]
15. [Plasminogenesis in blood of patients with chronic myeloproliferative syndromes].
Rość D; Kremplewska-Nalezyta E; Gadomska G; Drewniak W; Koczubik W
Pol Arch Med Wewn; 2006 Jan; 115(1):23-8. PubMed ID: 17278781
[TBL] [Abstract][Full Text] [Related]
16. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
[TBL] [Abstract][Full Text] [Related]
17. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
18. Influence of thrombopoietin on platelet activation in myeloproliferative disorders.
Usuki K; Iki S; Endo M; Izutsu K; Inoue K; Nishimura T; Urabe A
Br J Haematol; 1997 Jun; 97(3):530-7. PubMed ID: 9207394
[TBL] [Abstract][Full Text] [Related]
19. Hematopathologic findings in the myeloproliferative disorders.
Dickstein JI; Vardiman JW
Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders.
Katoh O; Kimura A; Kuramoto A
Am J Hematol; 1988 Apr; 27(4):276-80. PubMed ID: 3354562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
